pain
Charles River Laboratories to Manufacture AAV9 Vectors for Navega Therapeutics' Pain Gene Therapy
Navega was selected to be part of Charles River's cell and gene therapy accelerator program, which will provide it with manufacturing and advisory services.
Early results have shown that patients in the PGx-guided care arm have shorter hospital stays compared to those getting standard care.
Physicians are intrigued by the concept but want to see more data on the benefits of medical cannabis and on the underlying genetic links that can facilitate personalization.
Consortium Focused on Identifying Chronic Pain Biomarkers Gets $1.9M Boost
The additional funds from the National Institute on Drug Abuse will allow the Acute to Chronic Pain Signatures Consortium to keep researching biomarkers that can predict which patients are at risk.
In the PGx-ACT trial, investigators are tracking if patients unable to fully benefit from hydrocodone, tramadol, or codeine can get on the right drug with the help of genetic testing.